Side Effects of Risperidone
Risperidone causes a broad spectrum of adverse effects, with the most clinically significant being extrapyramidal symptoms (EPS), weight gain, metabolic disturbances, sedation, and cardiovascular events including cerebrovascular accidents—particularly in elderly patients with dementia.
Most Common Side Effects
Neurological Effects
The most prevalent neurological side effects include:
Extrapyramidal symptoms (EPS): Parkinsonism occurs in 14-28% of adult patients with schizophrenia, akathisia in 9-10%, dystonia in 3-6%, and tremor in 2-6% 1. These effects are dose-dependent, with EPS incidence ranging from 7% at 1 mg/day to 35% at 16 mg/day 1.
Sedation: Affects 10-63% of patients depending on dose and population, with pediatric patients showing rates up to 63% 1. This is consistently reported across treatment duration 2.
Dizziness: Occurs in 6-16% of patients across different indications 1.
Metabolic and Endocrine Effects
Weight gain is the single most common adverse effect, occurring in 57-68% of patients 3. This is accompanied by:
- Increased appetite: 44-48% of patients 3
- Hyperprolactinemia: Leading to sexual dysfunction, gynecomastia, galactorrhea, menstrual irregularities, and erectile dysfunction 4, 1
- Metabolic syndrome risk: Including diabetes mellitus and dyslipidemia 4
Critical caveat: Weight gain is paradoxically more prevalent at lower doses (68% at <4 mg/day vs 42% at ≥4 mg/day) 3, though the mechanism remains unclear.
Cardiovascular Effects
In elderly patients with dementia, risperidone carries severe cardiovascular risks:
- Cerebrovascular events: 4-fold increased risk (HR 4.11) with median onset at 4.3 weeks 5
- Major cardiovascular events: 2-fold increased risk (HR 2.00) with median onset at 4.8 weeks 5
- Orthostatic hypotension: 2% in adults 1
These risks are highest in older patients, males, and those already on cardiac medications 5.
Gastrointestinal Effects
- Nausea: 5-6%
- Constipation: 10-12%
- Salivary hypersecretion: 10-12% (particularly in pediatric populations) 1
Psychiatric Effects
- Insomnia: More common at standard doses (23%) than low doses (5%) 3
- Anxiety: 3-8%
- Paradoxically, anxiety and difficulty falling asleep may actually improve compared to placebo in some populations 6
Pediatric-Specific Considerations
In children and adolescents, the side effect profile differs somewhat:
- Somnolence: 37% vs 12% placebo 6
- Enuresis (bedwetting): 33% vs 29% placebo 6
- Weight gain: Increases by 0.5-0.6 standard deviations during acute treatment, with continued but decelerating gain over 6 months 6, 7
- Psychic symptoms: Tiredness, difficulty concentrating, difficulty remembering, and increased dreaming are common with longer exposure 2
Important: EPS rates in children are similar to placebo in most studies, though drooling is more common 6.
Time Course of Adverse Effects
The temporal pattern of side effects is clinically important:
- Immediate (0-4 weeks): Somnolence, sedation, orthostatic hypotension
- Early (4-8 weeks): Cerebrovascular and cardiovascular events peak 5, upper respiratory tract infections emerge 5
- Ongoing: Weight gain continues but decelerates over time 6
- Chronic: Extrapyramidal symptoms may worsen with prolonged exposure 2
Most serious adverse effects occur after 4 weeks of treatment 5, contradicting the notion that early tolerability predicts long-term safety.
Dose-Dependent Effects
Clear dose-response relationships exist for:
- EPS: Parkinsonism scores increase from 0.6 at 1 mg/day to 4.1 at 16 mg/day 1
- Overall EPS incidence: 7% at 1 mg/day to 35% at 16 mg/day 1
However, weight gain shows an inverse relationship, being more common at lower doses 3.
Rare but Serious Effects
Recent pharmacovigilance data 8 has identified additional concerning signals:
- Rare extrapyramidal effects: Propulsive gait, spasmodic dysphonia, tongue thrust, respiratory dyskinesia, oromandibular dystonia
- Cardiovascular: Wellens' syndrome, endocarditis fibroplastica
- Other: Rabbit syndrome (perioral tremor), jaw clicking, portal vein cavernous transformation, floppy iris syndrome
Overdose Presentation
Overdose manifests as exaggeration of known effects: drowsiness, sedation, tachycardia, hypotension, EPS, prolonged QT interval, and seizures 1. Torsade de pointes has been reported with combined risperidone-paroxetine overdose 1.
Clinical Implications
When prescribing risperidone, monitor closely for:
- Baseline and ongoing weight, BMI, metabolic parameters
- EPS using standardized scales, particularly after dose increases
- Cardiovascular risk factors in elderly patients—avoid use in dementia beyond 12-16 weeks per guidelines 9
- Prolactin-related symptoms
- Sedation impact on function, especially in first 4 weeks
Risk stratification is essential: Older age, male sex, and baseline cardiac medication use predict serious adverse outcomes 5. In these high-risk patients, alternative antipsychotics should be strongly considered.